Effect of lentivirus-mediated uPA silencing on the proliferation and apoptosis of chondrocytes and the expression of MMPs

Abstract

The lentivirus-mediated uPA interference in the proliferation, apoptosis, and secretion of osteoarthritic chondrocytes was examined in this study. Cells were obtained from the cartilage tissues of New Zealand white rabbits. They were cultured with interleukin (IL)-1β (10 ng/mL) for 24 h and then divided into three groups: uPA-siRNA group (cells transfected with uPA-siRNA lentiviruses), blank control group (untreated cells), and negative control group (cells transfected with empty vectors). Western blotting and real-time quantitative reverse transcription-PCR (RT-QPCR) were performed to detect the protein and mRNA expression levels of uPA, MMP-1, MMP-3, MMP-9, MMP-10, MMP-13 and MMP-14 in osteoarthritic chondrocytes. Cell Counting Kit-8, flow cytometry, and colony formation assay were used to examine the proliferation and apoptosis of chondrocytes. The results showed that after uPA-siRNA transfection, the protein and mRNA expression levels of uPA, MMP-1, MMP-3, MMP-9, MMP-10, MMP-13, and MMP-14 were significantly decreased (P<0.05 for MMP-1, MMP-9, MMP-10 and MMP-14, P<0.01 for uPA, MMP-3 and MMP-13). Cell proliferation and colony formation rate were significantly higher and the cell apoptosis rate was significantly lower in uPA-siRNA group than in control groups (P<0.01). The proportion of cells in G₀/G₁ phase was markedly increased and that in the S phase decreased, and the cell cycle was arrested at the G₁/S phase in the control group. In the uPA-siRNA group, the proportion of cells in the S phase was significantly increased, resulting in a different proportion of cells in cell cycle phase (P<0.01). It was suggested that the down-regulation of uPA gene could inhibit the expression of MMPs protein and cell apoptosis, increase the proliferation and colony formation of osteoarthritic chondrocytes.

Keywords

siRNA / uPA / chondrocytes / MMPs

References

[1] GonzalezA. Osteoarthritis year 2013 in review: genetics and genomics. Osteoarthritis Cartilage, 2013, 21(10): 1443-1451 PMID: 23845519

[2] Hawker GA, Stanaitis I. Osteoarthritis year in review 2014: clinical. Osteoarthritis Cartilage, 22(12):1953–1957

[3] LoeserRF. Osteoarthritis year in review 2013: biology. Osteoarthritis Cartilage, 2013, 21(10): 1436-1442 PMCID: 3779513 PMID: 23774472

[4] ArdenNK, LeylandKM. Osteoarthritis year 2013 in review: clinical. Osteoarthritis Cartilage, 2013, 21(10): 1409-1413 PMID: 23831667

[5] SunHB. Mechanical loading, cartilage degradation, and arthritis. Ann N Y Acad Sci, 2010, 1211: 37-50 PMID: 21062294

[6] Martel-PelletierJ, FaureMP, McCollumR, et al. . Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol, 1991, 18(12): 1863-1871 PMID: 1724464

[7] BurragePS, MixKS, BrinckerhoffCE. Matrix metalloproteinases: role in arthritis. Front Biosci, 2006, 11: 529-543 PMID: 16146751

[8] GarnerBC, StokerAM, KurokiK. Using animal models in osteoarthritis biomarker research. J Knee Surg, 2011, 24(4): 251-64 PMID: 22303754

[9] IrigoyenJP, Munoz-CanovesP, MonteroL, et al. . The plasminogen activator system: biology and regulation. Cell Mol Life Sci, 1999, 56(1–2): 104-132 PMID: 11213252

[10] DelRA, CinelliM, GuiducciS, et al. . Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes. Rheumatology, 2005, 44(10): 1255-1262

[11] DiehlP, HantkeB, HennigM, et al. . Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis. Int J Mol Med, 2004, 13(5): 711-715 PMID: 15067375

[12] LiH, FengF, BinghamCO, et al. . Matrix metalloproteinases and inhibitors in cartilage tissue engineering. J Tissue Eng Regen Med, 2012, 6(1): 144-154 PMID: 21351376

[13] ShiQ, ZhangXL, DaiKR, et al. . siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis. Expert Opin Biol Ther, 2011, 11(1): 5-16 PMID: 21058934

[14] FrohlichM, MalicevE, GorensekM, et al. . Evaluation of rabbit auricular chondrocyte isolation and growth parameters in cell culture. Cell Biol Int, 2007, 31(6): 620-625 PMID: 17293128

[15] NgoJC, JiangL, LinZ, et al. . Structural basis for therapeutic intervention of uPA/uPAR system. Curr Drug Targets, 2011, 12(12): 1729-1743 PMID: 21707478

[16] BreussJM, UhrinP. VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adh Migr, 2012, 6(6): 535-615 PMCID: 3547900 PMID: 23076133

[17] LajeunesseD. The role of bone in the treatment of osteoarthritis. Osteoarthritis Cartilage, 2004, 12(SupplA): S34-S38 PMID: 14698639

[18] NonakaT, KikuchiH, IkedaT, et al. . Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol, 2000, 27(4): 997-1004 PMID: 10782829

[19] BaoJP, ChenWP, FengJ, et al. . Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: regulation by dehydroepiandrosterone. Clin Chim Acta, 2009, 408(1–2): 1-7 PMID: 19589338

[20] PopaNL, WergedalJE, LauKH. Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling. J Bone Miner Metab, 2014, 32(1): 124-135 PMID: 23700285

[21] IshibashiH, NariaiY, KannoT, et al. . Effects of transforming growth factor beta 1 on the plasminogen activation system, collagen and integrin synthesis, and proliferation of rabbit mandibular condylar chondrocytes. Int J Oral Maxillofac Surg, 2014, 43(4): 470-475 PMID: 24252651

[22] KimKS, LeeYA, ChoiHM, et al. . Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13. Rheumatol Int, 2012, 32(10): 3069-3075 PMID: 21913037

[23] LavigneP, BenderdourM, LajeunesseD, et al. . Subchondral and trabecular bone metabolism regulation in canine experimental knee osteoarthritis. Osteoarthritis Cartilage, 2005, 13(4): 310-317 PMID: 15780644

[24] BurragePS, MixKS, BrinckerhoffCE. Matrix metalloproteinases: role in arthritis. Front Biosci, 2006, 11: 529-543 PMID: 16146751

[25] SaloJ, MackiewiczZ, IndahlA. Plasmin-matrix metalloproteinase cascades in spinal response to an experimental disc lesion in pig. Spine, 2008, 33(8): 839-844 PMID: 18404101

[26] Ramos-DeSimoneN, Hahn-DantonaE, SipleyJ, et al. . Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem, 1999, 274(19): 13066-13076 PMID: 10224058

[27] DreierR, GrasselS, FuchsS, et al. . Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res, 2004, 297(1): 303-312 PMID: 15212936

[28] HeardBJ, MartinL, RattnerJB, et al. . Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid. BMC Musculoskelet Disord, 2012, 13: 126-137 PMCID: 3532375 PMID: 22824140

[29] KoskinenA, VuolteenahoK, NieminenR, et al. . Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol, 2011, 29(1): 57-64 PMID: 21345293

[30] WangWS, ShiCH, LiCJ, et al. . Study on the correlation of uPA, MMP-3, 9, 13, 14 and joint function with knee osteoarthritis. Chin J Osteoporos (Chinese), 2014, 20(6): 602-607

[31] SatoT, TamaiH, KobayashiM, et al. . Immunohistochemical properties in the patients with Buerger’s disease—possible role of plasminogen activator inhibitor-1 for preservation of vessel wall architecture. Cardiovasc Pathol, 2011, 20(5): 266-271 PMID: 20708412

[32] KorshunovVA, SolomatinaMA, PlekhanovaOS, et al. . Plasminogen activator expression correlates with genetic differences in vascular remodeling. J Vasc Res, 2004, 41(6): 481-490 PMID: 15528930

[33] VisseR, NagaseH. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res, 2003, 92(8): 827-839 PMID: 12730128